Delivery Order SPE2DB25D3018-SPE2DB25FUYAX
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This is a firm fixed price delivery order with a completion date of September 2, 2025, with no set-aside designation applied. The contract represents a competitive award under DLA's broader pharmaceutical supply framework, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,411.43 under a firm fixed-price contract. The delivery order is non-set-aside and carries an ultimate completion date of September 4, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $16,453.58. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and no set-aside designation was used in the award. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $12,267.76 under a firm fixed-price contract. This non-competitive delivery order represents a continuation of medical pharmaceutical procurement through AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical, designated as SPE2DX, which carries a potential value of...
- The Defense Logistics Agency awarded a delivery order valued at $11,336.48 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct fulfillment order under AmerisourceBergen's broader contract vehicle with DLA. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This is a non-set-aside, competitively awarded contract with a firm fixed price ceiling value of $9,793.69 and a completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $27,454.56 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The contract employs firm fixed price terms with an ultimate completion date of September 16, 2025, and utilizes no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Actemra 162 mg/0.9 mL syringes, with a ceiling value of $23,369.56 and a firm fixed price structure. The delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. Performance is scheduled for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,600.42 to AmerisourceBergen Drug Corp for the supply of ACTEMRA 162 mg/0.9 mL syringes on July 28, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania location, with an ultimate completion date of July 29, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $16,194.07 delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on September 18, 2025, with an ultimate completion date of September 19, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The place of performance is listed as Conshohocken, PA. This delivery order is issued under...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB25FUYAXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that supplies a broad spectrum of pharmaceutical products and medical supplies to support military and veteran healthcare systems. This delivery order represents one of numerous pharmaceutical procurement transactions the company fulfills under its DLA prime contract vehicle, which enables supply of specialty medications, brand-name and generic drugs, vaccines, and related medical commodities to support Defense Health Agency operations and other government healthcare systems. The company's consistent receipt of competitively awarded contracts demonstrates its capability to meet stringent federal procurement standards across a diverse portfolio of medical products.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.6k | 7/22/25 |